Abstract
The blood, tumour and whole-body levels and survivals of 131I- and 111In-labelled monoclonal antibody (791T/36) have been compared in mice with human tumour xenografts. The blood levels and survivals of 131I- and 111In-labelled antibody were similar when expressed as proportions of the injected doses. However, the whole-body survival of 111In following administration of 111In-labelled antibody was over twice as long as that of 131I after administration of 131I-labelled antibody, principally because free 131I was rapidly excreted but free 111In was retained, primarily in liver, spleen and kidneys. Consequently, when expressed in relation to the whole body, blood levels of 131In became progressively lower than those of 131I following administration of labelled antibodies. In mice with human tumour xenografts the proportion of the injected dose of 111In from 111In-labelled antibody deposited in tumour tissue was 4–5 times higher than that of 131I from 131I-labelled antibody. When compared with the whole-body levels of radiolabel the difference was less marked, although 111In accumulation in tumour was more rapid. The higher levels and longer retention of 111In in tumour produced tumour-to-blood ratios that were 7–8 times those achieved with 131I-labelled antibody.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armitage NC, Perkins AC, Pimm MV, Wastie ML, Baldwin RW, Hardcastle JD (1985) Imaging of primary and metastatic colorectal cancer using an 111In-labelled antitumour monoclonal antibody (791T/36). Nucl Med Commun (in press)
Bazin H, Malet F (1969) The metabolism of different immunoglobulin classes in irradiated mice. I. Catabolism. Immunology 17:345–365
Dassin E, Eberlin A, Briere J, Dosne AM, Najean Y (1978) Metabolic fate of 111Indium in the rat. Int J Nucl Med Biol 5:34–37
Embleton MJ, Gunn B, Byers VS, Baldwin RW (1981) Antitumour reactions of monoclonal antibody against a human osteogenic sarcoma cell line. Br J Cancer 43:582–587
Fairweather DS, Bradwell AR, Dykes PW, Vaughan AT, Watson-James SF, Chandler S (1983) Improved tumour localization using indium-111 labelled antibodies. Br Med J 287:167–170
Fowler BA, Kardish RM, Woods JS (1983) Alteration of hepatic microsomal structure and function by indium chloride. Lab Invest 48:471–477
Galle P (1981) Mecanisme d'elimination renale de deux elements due groupe 111A de la classification periodique: l'aluminium et l'indium. CR Acad Sci Paris 292:91–96
Halpern SE, Hagan PL, Garver PR, Kozioc JA, Chen AWN, Fincke JM, Bartholomew RM, David GD, Adams TH (1983) Stability, characterization, and kinetics of 111In-labeled monoclonal antibodies in normal animals and nude mouse-human tumor models. Cancer Res 43:5347–5355
Izzo MJ, Bale WF (1976) Preferential localization and rate of loss of labeled alloantibody from rat tumours and skin transplants carrying the corresponding alloantigen. Cancer Res 36:2868–2873
Larson SM, Carrasquillo JA (1984) Nuclear oncology 1984. Semin Nucl Med 14:268–276
Perkins AC, Pimm MV (1985) Differences in tumour and normal tissue concentrations of indium and iodine labelled monoclonal antibody. I. The effect on image contrast in clinical studies. Eur J Nucl Med (in press)
Perkins AC, Pimm MV, Birch MK (1985). The preparation and characterisation of 111In-labelled 791T/36 monoclonal antibody for tumour immunoscintigraphy. Eur J Nucl Med 10:296–301
Perper RJ, Najarian JS (1968) Host fixation and kinetics of antitissue antibodies. Transplantation 6:833–843
Pimm MV, Embleton MJ, Perkins AC, Price MR, Robins RA, Robinson GR, Baldwin RW (1982) In vivo localization of antiosteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts. Int J Cancer 30:75–85
Rainsbury RM (1984) The localization of human breast carcinomas by radiolabelled monoclonal anbitodies. Br J Surgery 71:805–812
Rainsbury R, Westwood J (1982) Tumour localization with monoclonal antibody radioactively labelled with metal chelate rather than iodine. Lancet II:1347–1348
Scheinberg DA, Strand M (1983) Kinetic and catabolic considerations of monoclonal antibody targeting in erytholeukaemic mice. Cancer Res 43:265–273
Stern P, Hagan P, Halpern S, Chen A, David G, Adams T, Desmond W, Brautigam K, Roytston I (1982) The effect of the radiolabel on the kinetics of monoclonal anti-CEA in a nude mouse-human colon tumor model. In: Mitchell MS, Oettgen FHF (eds) Hybridomas in cancer diagnosis and treatment. Raven Press, New York, pp 245–253
Wahl RL, Sherman P, Fisher S (1984) The effect of specimen processing on radiolabeled monoclonal antibody distribution. Eur J Nucl Med 9:382–384
Winchell HS (1976) Mechanisms for localisation of radiopharmaceuticals in neoplasms. Semin Nucl Med 6:371–378
Wochner RD, Adatepe M, Van Amburg A, Potchen EJ (1970) A new method for estimation of plasma volume with the use of the distribution space of indium — 113m-transferrin. J Lab Clin Med 75:711–720
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pimm, M.V., Perkins, A.C. & Baldwin, R.W. Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody.. Eur J Nucl Med 11, 300–304 (1985). https://doi.org/10.1007/BF00252341
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00252341